Recent Headlines
Huntington Study Group Announces Executive Director of Clinical Operations
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to introduce Carolyn Schultz-Walter as the Executive Director of Clinical Operations. With over 25 years of global clinical operations experience spanning both sponsor and clinical research... - March 31, 2025 - Huntington Study Group
Carl Wittwer, MD, PhD, Joins PathogenDx’s Board of Advisors
Carl Wittwer, MD PhD, Professor Emeritus of Pathology at the University of Utah, a Co-Founder of Idaho Technologies/Biofire and previously spent 35+ years as a Medical Director at ARUP Laboratories is joining PathogenDx as Technology & Scientific Board Advisor to help advance its D3 Array technology in terms of Speed, Cost and Performance. - March 25, 2025 - PathogenDx, Inc.
Thar Process and Clean Heat Technologies Integrate CO2 Heat Pump Technology to Make Supercritical CO2 Technology a Low Cost Solution
Thar Process and Clean Heat Technologies have successfully engineered, integrated and installed electric heat pumps using CO2 - R744 - as the upcycled, natural refrigerant. The technology partnership means that Thar Process' clients can benefit from lower operating costs. Thar is known for it's innovative use of CO2 for extracting flavors, fragrances, medicinal and therapeutic compounds both in it's GMP certified facility in Pittsburgh and at client sites globally. - March 24, 2025 - Thar Process
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025 - SignaBlok, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025 - SignaBlok, Inc.
ALS Therapy Development Institute Joins DataCite to Expand Access and Impact of ARC Dataset
The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the... - March 18, 2025 - ALS Therapy Development Institute
ConductScience Accepted Into NVIDIA Connect Program, Advancing AI-Driven Behavioral Neuroscience Research Solutions
ConductScience joins the NVIDIA Connect program, accelerating AI advancements in behavioral research. This collaboration enhances ConductVision, ConductInsecta, ConductNest, and GaitMaster, optimizing research on locomotion, cognition, and social behavior across species. With NVIDIA’s support, ConductScience gains access to GPU-accelerated computing, engineering resources, and training, driving innovation in neuroscience, genetics, and medicine. - March 16, 2025 - ConductScience
Regenexx® Corporate Program's Dr. Mark Testa Wins the YOU Powered Symposium 2025 Most Influential Clinician in Insurance Award
The YOU Powered Symposium is the leading annual event for "bold benefits trailblazers." It brings together hundreds of benefit professionals, solution providers, clinicians, and employers to combine diverse expertise in an effort to reform the US healthcare system on behalf of every patient. - March 04, 2025 - Regenexx Corporate Program
AI MINDSystems Foundation and GenoBank.io Announce Strategic Partnership at ETHDenver to Advance Decentralized Biobanking and Healthcare Innovation
AI MINDSystems and GenoBank.io partner at ETHDenver to advance decentralized biobanking. Integrating GenoBank.io’s BioNFT™ into the AI MINDSystems Trusted Data Ecosystem™ empowers individuals with control over their biosamples via ‘lockable’ NFTs. This collaboration aims to create secure, privacy-preserving solutions for digital biology, precision health, and research, using blockchain and Web3 technologies. They also plan to launch WISDOM Networks™ for data-driven healthcare transformation. - February 28, 2025 - AI MINDSystems Foundation
Trump-Era Administration Drug Development & Outsourcing Impact Report
How Tariffs and RFK Jr.’s HHS Appointment May Shift Drug Development & Outsourcing - February 27, 2025 - Life Science Strategy Group, LLC
Purity Health, LLC Announces Lora Harnack as New Chief Executive Officer
Purity Health, LLC has appointed Lora Harnack as its new Chief Executive Officer, with former CEO Rob Bramblett transitioning to President. Harnack, a Tennessee native with 30 years of healthcare leadership experience, has held executive roles in hospital administration, healthcare IT, and nonprofit organizations, most recently leading the Cumberland Pediatric Foundation. - February 21, 2025 - Purity Health, LLC
PathogenDx Launches Its Rebranded D3 Array™ Combined, Bacterial and Fungal Assays—Delivering Value in Turn-Around Time, Cost and Throughput to Testing Labs
PathogenDx, a leader in next-generation microarray technology for better health and safety, announced the launch of its new rebranded D3 Array™ Combined, Bacterial and Fungal assays to replace Detectx–Combined,Detectx-Bacterial and Detectx-Fungal tests. - February 20, 2025 - PathogenDx, Inc.
Biovenic Scripts a New Chapter to Boom Veterinary Diagnostics
Biovenic, a powerhouse in veterinary research, transforms the way to detect and manage animal diseases, spotlighting innovative animal disease diagnostic solutions that answer the rising demand for exact and precise veterinary diagnostics worldwide. - February 12, 2025 - Biovenic
Rajesh (Raj) B. Shah Joins CR&T Board of Directors to Advance Cancer Research and Treatment
The Cancer Research & Treatment Fund, Inc. (CR&T) proudly announces the appointment of Rajesh (Raj) B. Shah to its esteemed Board of Directors. Raj brings a wealth of experience and passion to CR&T’s mission of advancing the fight against cancer. His appointment reinforces the... - January 29, 2025 - The Cancer Research & Treatment Fund, Inc.
Hemanext Announces Close of Series B-2 Equity Funding Round
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces close of series B-2 equity fundraising round. The B-2 fundraising was launched in May 2024 to raise $16-20 million and was completed in October 2024, raising just over $20 million at a pre-money... - January 27, 2025 - Hemanext
Physicians Research Group and bioaccess® Join Forces to Expand Clinical Trial Opportunities in South America
Physicians Research Group (PRG), a leading clinical trial site network and bioaccess®, Latin America’s premier contract research organization (CRO), are proud to announce a strategic collaboration aimed at advancing clinical research and increasing access to innovative treatments across South America. - January 07, 2025 - Physicians Research Group
Ales for ALS Achieves $1 Million Milestone and Expands Nationwide
Ales for ALS™, a global initiative uniting craft breweries in the fight against ALS, has reached an extraordinary milestone in 2024: raising $1 million in a single year. Supported by Yakima Chief Hops, this program has seen remarkable growth over its 13-year journey, fueled by the dedication of brewers, sponsors, and a passionate community. - January 06, 2025 - ALS Therapy Development Institute
Hemanext Inc. Announces First Patients Treated in a Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces that the first two patients enrolled have begun receiving transfusions in a multi-center, randomized, controlled cross-over study to evaluate the safety and effectiveness of hypoxic red blood... - December 20, 2024 - Hemanext
Augie’s Quest to Cure ALS Completes $5.8 Million Commitment to Fund ALS TDI’s Translational Research Center
The ALS Therapy Development Institute (ALS TDI) is proud to announce that Augie’s Quest to Cure ALS has fulfilled its $5.8 million commitment, pledged in 2021, to advance ALS research. This transformative funding has directly supported the Augie’s Quest Translational Research Center... - December 13, 2024 - ALS Therapy Development Institute
Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research
Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research. Dr. - December 11, 2024 - Regenexx Corporate Program
SeroRepair Announces New Office Location to Support Expansion and Growth
SeroRepair, an eye serum leader in the veterinary industry announces expansion to a new office location for increased operations, customer service, and product development, positioning the company for continued success in the veterinary industry. With an ever-growing demand for high-quality eye care products for small and large animals and a need for increasing efficiency in veterinary practices, SeroRepair has experienced significant growth over the past year. - December 10, 2024 - SeroRepair
Arizona Pharmacy Association Appoints Garet Turner as New CEO
Today, the Arizona Pharmacy Association (AzPA), the leading voice for Arizona’s pharmacy professionals, announced the appointment of Garet Turner as its new Chief Executive Officer. Turner, a seasoned management, membership and fundraising professional will take the helm on January... - December 07, 2024 - Arizona Pharmacy Association
Life's Transformations: The Yellow Butterfly's Lupus Experience
Rosemarie K. Witter Foundation (RKW), a not-for-profit organization dedicated to promoting medical research in finding effective treatment, leading to a cure for Lupus, is thrilled to announce the upcoming original performance of The Yellow Butterfly: A Lupus Story Benefit Play. This event aims to... - November 06, 2024 - Rosemarie K. Witter Foundation, Inc.
Synaps Dx Launches Digital Cognitive Screening and Alzheimer’s Testing with BrainCheck and Clarity Health Clinics
Synaps Dx, BrainCheck, and Clarity Health introduce an innovative online Alzheimer's and cognitive health screening tool, accessible from home. Launching in Texas, with nationwide expansion planned, this telehealth solution provides families with a convenient, reliable path to early detection during National Alzheimer’s Disease Awareness Month, reducing the need for in-office visits and empowering proactive cognitive care. - November 04, 2024 - SynapsDx
Hemanext Signs Agreement with Hemara Bio in the U.A.E., Marking the Initiation of Commercialization Activities in the GCC Region
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announced that it has entered into an exclusive distribution agreement with Hemara Bio in Dubai, United Arab Emirates (UAE) to bolster its sales capabilities across the Gulf Countries strengthening its relationships with key blood centers and clinicians in the region. - October 31, 2024 - Hemanext
Novugen Pharma Malaysia Achieves Zero Form 483 Citations in Recent USFDA Audit
Novugen Pharma Sdn. Bhd. proudly announces the successful completion of recent USFDA audit, achieving zero Form 483 citations and No Action Indicated (NAI) status—the highest level of compliance for USFDA-registered manufacturing facilities. This milestone positions Novugen among a select few global companies meeting these standards and reflects the dedication of its team. - October 29, 2024 - Novugen
October is Havana Syndrome Awareness Month
October is Havana Syndrome Awareness Month. The purpose is to raise awareness about Havana Syndrome injuries caused by directed energy. - October 05, 2024 - Havana Syndrome, Inc.
Canaritech Announces the Launch of Operations, Offering Comprehensive Clinical Trial Solutions Across Latin America
Canaritech, a Contract Research Organization (CRO), has officially launched operations across Latin America, with offices in Mexico, Peru, Chile, and Colombia. The company offers a range of clinical trial services, including regulatory consulting, trial management, decentralized clinical trials, and post-market studies. Canaritech aims to drive innovation in clinical research by improving trial efficiency and increasing patient access through localized expertise and advanced technologies. - September 22, 2024 - Canaritech
Superior Rail & Iron Works Named First-Ever Diamond Sponsor for ALS TDI’s White Coat Affair Gala
The ALS Therapy Development Institute (ALS TDI) has announced that Superior Rail & Iron Works, Inc. will be the first-ever Diamond Sponsor for the annual White Coat Affair gala, taking place on October 5, 2024, at the Boston Sheraton. Superior Rail & Iron Works, Inc., which was the gala’s Title Sponsor last year, is continuing its support, helping ALS TDI push forward with critical research to find treatments for ALS. - September 19, 2024 - ALS Therapy Development Institute
Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit”
The Centers for Medicare & Medicaid Services (CMS) has officially issued a new Healthcare Common Procedure Coding System (HCPCS) code for “Red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced, each unit,” an innovative blood transfusion product produced by the Hemanext ONE Red Blood Cell Processing and Storage System. - September 09, 2024 - Hemanext
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group
ALS Therapy Development Institute Commemorates 25th Anniversary at the Leadership Weekend in October
Taking place from October 3-5, 2024, in the Boston area, ALS TDI’s Leadership Weekend features a series of community-focused events, including an Open House at ALS TDI’s cutting-edge research lab, the ALS TDI Research Summit, and the White Coat Affair gala. - September 03, 2024 - ALS Therapy Development Institute
Huntington Study Group Announces New CEO
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group
Hemanext Inc. Announces Completion of Cancer and Burn Safety Study, a Significant Milestone for the Hemanext ONE® Innovative Red Blood Cell Processing and Storage System
The post-market clinical study in Bergen, Norway, that was designed to assess the safety of transfusing hypoxic red blood cells (RBCs) in patients with acute burns and hematological malignancies, has been completed. - August 20, 2024 - Hemanext
Minus K Technology Announces Its Ninth Educational Giveaway of Vibration Isolators to U.S. Colleges and Universities
Minus K Technology announces its Educational Giveaway of Vibrations Isolators to U.S. Colleges and Universities. - August 05, 2024 - Minus K Technology Inc.
SYNAPS Dx Welcomes Renowned Alzheimer’s Researcher, Dr. Donna Wilcock, to Its Scientific Advisory Board
SYNAPS Dx welcomes Dr. Donna M. Wilcock, a leading Alzheimer's researcher, to its Scientific Advisory Board. Dr. Wilcock's expertise in neuroinflammation and vascular cognitive impairment will support the advancement of the DISCERN™ diagnostic test for Alzheimer's disease. This addition reinforces SYNAPS Dx’s commitment to pioneering accurate, minimally invasive diagnostics for Alzheimer's. For more info, visit SYNAPS Dx's website. - July 15, 2024 - SynapsDx
Huntington Study Group Announces Launch of LEAD-HD Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group
SYNAPS Dx Announces Expansion to New, State-of-the-Art Facility
SYNAPS Dx has moved to a new, state-of-the-art facility in Rockville, MD, to meet growing demand and enhance patient care. The larger space and advanced infrastructure will support more diagnostic samples and ensure timely, accurate Alzheimer's and dementia diagnoses. Fully qualified for high-complexity clinical lab testing, the facility boosts diagnostic capabilities. The expansion will also advance the DISCERN™ test, a minimally invasive tool distinguishing Alzheimer's from other dementias. - June 26, 2024 - SynapsDx
Cambridge Polymer Group Unveils Restructure to Accelerate Client Innovation through Material Science
Cambridge Polymer Group (CPG) announced a new leadership structure to better support clients in developing innovative products. CPG is creating a new five-person senior management team with deep materials science expertise, which will allow for closer collaboration with clients on complex projects. Dr. Gavin Braithwaite will be the new CEO and Dr. Stephen Spiegelberg will move to the new role of Chief Scientific Officer (CSO). - June 23, 2024 - Cambridge Polymer Group
Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com
Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company
Novugen Launches Pazopanib Tablets, 200mg, in the U.S. Following ANDA Approval by USFDA
Novugen has launched Pazopanib tablets, 200mg, in the U.S. after receiving ANDA approval from USFDA on April 23, 2024. This significant milestone demonstrates Novugen's continued growth in the U.S. pharmaceutical market with a complex anticancer drug, the generic equivalent of Votrient, used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). - May 07, 2024 - Novugen
Limited Opportunity: Enroll in Ales for ALS 2024 Today, Secure Your Spot as Part of a Growing National Movement
Ales for ALS invites brewers to craft distinctive and flavorful beers using a custom hop blend generously donated by Yakima Chief Hops. In exchange, participating brewers pledge to donate $1 for every pint sold, directly contributing to groundbreaking ALS research at the ALS Therapy Development Institute (ALS TDI). - May 04, 2024 - ALS Therapy Development Institute
No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption
Thar Process, with 34 years of expertise in supercritical fluid extraction, has developed a sustainable way to produce de-fatted lecithin powder that has less oil and longer shelf-life stability. The new process is semi-continuous and sustainable because it utilizes upcycled CO2 from waste sources instead of using toxic acetone which is the industry standard. - April 26, 2024 - Thar Process
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This... - April 25, 2024 - ALPCO
The °C Rail with Slidable Sensors is the Latest Addition to the Degree Controls Platform of Multipoint Airflow Instrumentation
The all-new °C Rail multipoint airflow instrumentation system from Degree Controls is designed with a versatile array of slidable sensors to accommodate changing test setups. - April 15, 2024 - Degree Controls
Huntington Study Group Launches Project AWARE 2.0 Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group
Minus K Congratulates to the Winners of Their 2023/2024 Educational Giveaway
Minus K congratulates the four winners of the Minus K's 2023/2024 Educational Giveaway. Over $75,000 of new passive mechanical hub hertz vibration isolators have been granted to universities and colleges in the U.S. over the last ten years. - April 10, 2024 - Minus K Technology Inc.
MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq
MENADNA Inc., has entered into an exclusive partnership with ProPhase Labs' subsidiary, Nebula Genomics, aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities to improve the quality and relevance of genomic data in these historically underserved regions. - March 18, 2024 - MENADNA
iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease
iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.
Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer
Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. - March 11, 2024 - Defined Bioscience Inc.